Tividenofusp Alfa-Eknm
Brand Names: Avlayah
Methodology & AI Transparency ⓘ
Tividenofusp Alfa-Eknm Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage avlayah: is indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.
- 2 Real-world patient consensus: Real-world cohort score of 75% across 14 de-identified Tividenofusp Alfa-Eknm entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $127.17 mail/discount cash up to $311.57 uninsured retail (federal NADAC $2.9300).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Tividenofusp Alfa-Eknm include headache (10.7%), diarrhea (9.4%), vomiting (5.7%).
Ask our AI Specialists anything about Tividenofusp Alfa-Eknm
Tividenofusp Alfa-Eknm Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage avlayah: is indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. This indication is approved under accelerated approval based on the reduction of cerebrospinal fluid heparan sulfate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
12.1 Mechanism of Action Hunter syndrome is an inherited X-linked recessive lysosomal storage disease caused by a deficiency of iduronate-2-sulfatase (IDS), a lysosomal enzyme, that degrades heparan sulfate (HS) and dermatan sulfate (DS), the two primary glycosominoglycans (GAGs) in the lysosome. Insufficiency or absence of IDS leads to accumulation of GAGs, including HS and DS, and subsequent lysosome dysfunction in multiple organs and tissues, including the central nervous system (CNS). Tividenofusp alfa-eknm provides an exogenous source of IDS.
Systemic exposure to Tividenofusp Alfa-Eknm reflects Complete (~100%) parenteral systemic delivery for Tividenofusp Alfa-Eknm (150 mg/5mL Injection, Powder, Lyophilized, for Solution) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of tividenofusp alfa-eknm, sustaining receptor engagement across a Mean elimination half-life of 7 to 18 hours across adult Tividenofusp Alfa-Eknm dosing half-life window (rapid intravascular/parenteral onset within 15–45 minutes after tividenofusp alfa-eknm administration response profile).
Dosing protocols (150 mg/5mL Injection, Powder, Lyophilized, for Solution or Response-guided Tividenofusp Alfa-Eknm dose modification under follow-up) balance efficacy (75.00% patient satisfaction across 14 logs) against headache (10.7% of reports), diarrhea (9.4% of reports), nasopharyngitis (8.8% of reports), with strict avoidance in history of severe allergic sensitivity to tividenofusp alfa-eknm active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-03-20 tividenofusp alfa-eknm labeling.
Verify medication reconciliation lists so Tividenofusp Alfa-Eknm is not inadvertently duplicated with another hydrolytic lysosomal glycosaminoglycan-specific enzyme.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Tividenofusp Alfa-Eknm dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Tividenofusp Alfa-Eknm active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-03-20 Tividenofusp Alfa-Eknm labeling
Logged Side-Effect Incidence (14 Reports)
Tividenofusp Alfa-Eknm Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tividenofusp Alfa-Eknm)
Human clinical trial evidence for Tividenofusp Alfa-Eknm is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Tividenofusp Alfa-Eknm Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.9300/unit (~$87.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $311.57 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $127.17 / mo | View logs ↓ |
Tividenofusp Alfa-Eknm Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tividenofusp Alfa-Eknm RxNorm Concept ID | 2740019 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.9300 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $311.57 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $127.17 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 75.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tividenofusp Alfa-Eknm Patient Community, Cohort Filters & Dosage Logs
Deterministic Tividenofusp Alfa-Eknm reference combining NIH RxNorm (2740019), Medicaid NADAC ($2.9300/unit), and anonymous cohort outcomes (75% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tividenofusp Alfa-Eknm community threads and patient logs by age, biological sex, dosage, and treatment duration.